Posts by Amy Raskopf

First Patient Dosed in Phase 2 Study of PARP/Tankyrase Inhibitor 2X-121 for Metastatic Breast Cancer

CAMBRIDGE, Mass. and HOERSHOLM, Denmark, June 26, 2018 — Oncology Venture US Inc., Oncology Venture AB (OV:ST) (“OV”) and Medical...

June 1, 2018, 4:09pm CDT: Oral Presentation of 2X-121 Abstract at ASCO 2018

Ruth Plummer, MD, PhD, FRCP, will present an abstract describing the first-in-human Phase 1 study of 2X-121, an investigational PARP 1/2...

Abstracts on Three Pipeline Products Selected for 2018 ASCO Clinical Meeting

  Phase 1 Study of PARP Inhibitor 2X-121 Selected as Oral Presentation June 1, 2018 Hoersholm, Denmark and Cambridge, MA...

2X Oncology to Participate in Two Upcoming Investor Conferences

  Cambridge, MA – October 25, 2017 — 2X Oncology, Inc. (“2X” or the “Company”), a precision medicine company developing...

2X Oncology at ESMO 2017

2X Oncology’s Chief Medical Officer Marie Foegh, MD, DrSc, will be attending ESMO 2017, the annual meeting of the European...

2X Oncology Announces Validation of Drug Response Predictor (DRP) for its PARP Inhibitor 2X-121

— Developed DRP Successfully Identified Responders and Non-responders to Treatment with 2X-121 in 13-Patient Blinded Study —  Cambridge, MA – August...

Oncology Venture and Eisai Forge Exclusive Global License Agreement for Clinical Stage Oncology Drug PARP Inhibitor E7449 / 2X-121

2X Oncology to conduct Phase 2 Study of 2X-121 in metastatic breast cancer patients Hoersholm, Denmark, and Cambridge, MA, July...

2X Oncology Obtains Investigational New Drug Application for 2X-111 Glutathione Enhanced PEGylated Liposomal Doxorubicin

Cambridge, MA – June 8, 2017 — 2X Oncology, Inc. (“2X” or the “Company”), a precision medicine company developing targeted...

2X Oncology at Jefferies Global Healthcare Conference (webcast)

Our chief executive officer, George O. Elston, will present at the Jefferies 2017 Global Healthcare Conference. Date: Friday, June 9,...

2X Oncology to Present at Jefferies Global Healthcare Conference

  Cambridge, MA — May 31, 2017 — 2X Oncology, Inc. (“2X” or the “Company”), a company focused on developing...